Literature DB >> 25574922

Market assessment of tuberculosis diagnostics in South Africa, 2012-2013.

.   

Abstract

OBJECTIVE: To assess the current served available market of tuberculosis (TB) diagnostics in South Africa in the public and private sectors.
DESIGN: Public and private sector test volumes and unit costs were collected for tuberculin skin tests, interferon-gamma release assays, smear microscopy, culture, speciation, Xpert MTB/RIF, other nucleic acid amplification tests, drug susceptibility testing and adenosine deaminase tests.
RESULTS: In 2012, during Xpert scale-up, the public and private sectors performed a total of 9.2 million TB diagnostic tests, at an estimated total value of US$98 million. The public sector accounted for 93% of the overall test volume and value. There were no major differences in the types of tests performed in both sectors, with microscopy and culture accounting for the majority of tests performed (72%). In 2013, the public sector market value increased to US$101 million (a 10% increase over 2012): Xpert volumes increased by 166%, while total TB test volumes decreased by 12% compared to 2012.
CONCLUSION: South Africa has a substantial TB diagnostic market in terms of both volume and value. The roll-out of Xpert provides insights into how markets change in volume and value with the introduction of new tools.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25574922     DOI: 10.5588/ijtld.14.0565

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

1.  Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa.

Authors:  Karla Therese L Sy; Sarah V Leavitt; Margaretha de Vos; Tania Dolby; Jacob Bor; C Robert Horsburgh; Robin M Warren; Elizabeth M Streicher; Helen E Jenkins; Karen R Jacobson
Journal:  Sci Rep       Date:  2022-06-27       Impact factor: 4.996

Review 2.  Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects.

Authors:  Madhukar Pai; Marco Schito
Journal:  J Infect Dis       Date:  2015-04-01       Impact factor: 5.226

3.  Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.

Authors:  Denise Evans; Kathryn Schnippel; Caroline Govathson; Tembeka Sineke; Andrew Black; Lawrence Long; Rebecca Berhanu; Sydney Rosen
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

4.  The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges.

Authors:  Pren Naidoo; Grant Theron; Molebogeng X Rangaka; Violet N Chihota; Louise Vaughan; Zameer O Brey; Yogan Pillay
Journal:  J Infect Dis       Date:  2017-11-06       Impact factor: 5.226

5.  Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis.

Authors:  Avery I McIntosh; Helen E Jenkins; Laura F White; Marinus Barnard; Dana R Thomson; Tania Dolby; John Simpson; Elizabeth M Streicher; Mary B Kleinman; Elizabeth J Ragan; Paul D van Helden; Megan B Murray; Robin M Warren; Karen R Jacobson
Journal:  PLoS Med       Date:  2018-08-21       Impact factor: 11.069

Review 6.  Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa.

Authors:  Sarah V Leavitt; Karen R Jacobson; Elizabeth J Ragan; Jacob Bor; Jennifer Hughes; Tara C Bouton; Tania Dolby; Robin M Warren; Helen E Jenkins
Journal:  Emerg Infect Dis       Date:  2021       Impact factor: 6.883

7.  Early interactions with newly diagnosed TB patients in hospital can support linkage to care.

Authors:  L Viljoen; P Hendricks; G Hoddinott; N Vanqa; M Osman; A C Hesseling; S-A Meehan
Journal:  Public Health Action       Date:  2022-09-21

8.  Mycobacterium tuberculosis infection in a HIV-positive patient.

Authors:  Maria Theresa Montales; Alexandria Beebe; Arun Chaudhury; Naveen Patil
Journal:  Respir Med Case Rep       Date:  2015-10-27

9.  C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial.

Authors:  Henrik Aggerbeck; Morten Ruhwald; Søren T Hoff; Bettine Borregaard; Elizabeth Hellstrom; Mookho Malahleha; Mirna Siebert; Mashra Gani; Vincent Seopela; Andreas Diacon; Madeleine Lourens; Peter Andersen; Keertan Dheda
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.